shengnuo biotechnology 2021 performance will grow steadily and will accelerate the pace of R&D innovation and internationalization Broadcast article

On April 26, Chengdushengnuo biotechnology Co., Ltd.

(hereinafter referred to as “shengnuo biotechnology”) disclosed its 2021 annual report. The company achieved operating income of 387 million yuan last year, a year-on-year increase of 2.05%, net profit attributable to shareholders of the listed company was 61.2528 million yuan, a year-on-year increase of 2.09%, and net profit after deduction was 58.1 million yuan, a year-on-year increase of 12.38%.

In 2021, shengnuo biotechnology will focus on the strategic development goals of peptide APIs and preparations and peptide drug CDMO services. On the one hand, it will actively respond to the challenges of the new crown pneumonia epidemic. While doing a good job in epidemic prevention, it will actively put into operation and put into production, strictly control the quality, and ensure the production plan.

On the other hand, it adheres to the highest standards to meet customer needs, focusing on innovation and upgrading of the R&D system, optimizing the layout of production lines, and keeping up with the direction of innovative drug R&D, promoting the rapid expansion of peptide drug CDMO service projects and accelerating the process of overseas business development.

During the reporting period, as the CDMO projects of many of the clients served by the Company entered the clinical trial stage, and the preparations of overseas clients of APIs were approved for listing, the Company’s business maintained a trend of stable development.

The annual report shows that in 2021, preparations, APIs, pharmaceutical research, customized production, and entrusted processing businesses will contribute operating income of 178 million yuan, 90.5695 million yuan, 63.0417 million yuan, 15.6615 million yuan and 22.464 million yuan to shengnuo biotechnology.

The company’s API sales, pharmaceutical research and outsourced processing services achieved year-on-year growth. In terms of regions, the domestic and overseas operating income were 310 million yuan and 59.4321 million yuan respectively. Among them, the overseas operating income increased by 75.97% year-on-year. The company said that this is mainly due to the approval of the company’s APIs for overseas customers. due to increase.

From the perspective of research and development, in 2021, shengnuo biotechnology will focus on the research and development, production and sales of polypeptide drugs, and will continue to provide pharmaceutical research services for new drug research and development companies and scientific research institutions. One of them has been approved for listing and entered the commercialization stage , 10 innovative peptide drugs entered the clinical trial stage.

shengnuo biotechnologylogical believes that the entire peptide industry is still in a period of rapid development, and the market scale still has a large room for development. With the continuous adjustment of medical insurance measures and the full implementation of policies such as adjuvant drugs and “4+7”, the company will seize the development opportunities, product access and market access standards will continue to improve, and the peptide pharmaceutical industry will be more specialized , marketization and internationalization.

In 2022, the company will continue to focus on the peptide pharmaceutical industry, pay close attention to the development trend of the industry, and take “strengthening core competitiveness, accelerating production capacity improvement, and improving team management energy efficiency” as the main business idea. Accelerate the pace of R&D innovation and internationalization, increase the market development and channel construction of core APIs and preparations, do a good job in the integration of the industrial chain, and improve management efficiency; strengthen the polypeptide CDMO service business and lay a solid foundation for sustainable development.

In addition, shengnuo biotechnology also disclosed the first quarterly report of 2022 on April 26. In the first three months of this year, the company’s operating income and net profit attributable to shareholders of listed companies were 80.7448 million yuan and 14.2929 million yuan respectively.